Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC10547 | X-376 Featured |
X-376 is a highly selective and potent inhibitor of ALK (anaplastic lymphoma kinase) tyrosine kinase, demonstrating strong activity with an IC50 of 0.61 nM. While it primarily targets ALK, it also exhibits inhibitory effects on MET kinase, though with slightly reduced potency (IC50 = 0.69 nM). Due to its robust kinase-blocking properties, X-376 shows significant anti-tumor efficacy, making it a promising candidate for cancer research and therapeutic development.
More description
|
![]() |
DC74596 | Zilurgisertib fumarate |
Zilurgisertib fumarate(INCB-000928 fumarate, NBU-928 fumarate) is a selective ALK 2 inhibitor.It is under development for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
More description
|
![]() |
DC74377 | Ficonalkib |
Ficonalkib is a potent, selective anaplastic lymphoma kinase (ALK) inhibitor for treating an ALK-mediated disease.
More description
|
![]() |
DC74376 | Ensartinib dihydrochloride |
Ensartinib (X-396) dihydrochloride is a potent, selective and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with biochemical IC50 of <0.4 nM, inhibits MET with IC50 of 0.74 nM.
More description
|
![]() |
DC10463 | Repotrectinib(TPX-005) Featured |
Repotrectinib(TPX-005) is a multi-target macrocycle inhibitor of anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase receptor (TRK)
More description
|
![]() |
DC7359 | Asp-3026 Featured |
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.
More description
|
![]() |
DC40846 | TL13-22 Featured |
TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. TL13-22 does not degrade ALK in cells.
More description
|
![]() |
DC7451 | LDN-193189 HCl Featured |
LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.
More description
|
![]() |
DC72897 | J-1048 |
J-1048 is an activin receptor-like kinase 5 (ALK5) inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway.
More description
|
![]() |
DC45792 | TPX-0131 Featured |
TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). TPX-0131 has strong antitumor activities.
More description
|
![]() |
DC2047 | Crizotinib (PF-2341066) Featured |
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.
More description
|
![]() |
DC7924 | PF06463922(Lorlatinib) Featured |
PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
More description
|
![]() |
DC7303 | NVP-TAE684 Featured |
NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.
More description
|
![]() |
DC7383 | CH5424802(Alectinib) Featured |
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
More description
|
![]() |
DC40847 | TL13-110 |
TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. TL13-110 does not degrade ALK in cells.
More description
|
![]() |
DC71639 | Envonalkib citrate |
Envonalkib citrate is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer.
More description
|
![]() |
DC71181 | J-1063 |
J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis.
More description
|
![]() |
DC70910 | XMU-MP-5 |
XMU-MP-5 is a new-generation potent and selective ALK inhibitor (IC50=4.15 nM) to overcome crizotinib resistance mutations, including L1196M and G1202R;
XMU-MP-5 significantly induced apoptosis in EML4-ALK Ba/F3 cells did not affect apoptosis in wild-type Ba/F3 cells.
XMU-MP-5 shows highest binding affinities for ALK and its mutants ALK(C1156Y) and ALK(L1196M), with K d values of 0.57, 0.4, and 0.77 nM, respectively.
XMU-MP-5 blocks ALK signaling pathways and inhibits the proliferation of cells harboring either wild-type or mutant EML4-ALK in vitro and suppresses tumor growth in xenograft mouse models in vivo.
XMU-MP-5 induces significant regression of lung tumors in two genetically engineered mouse (GEM) models.
More description
|
![]() |
DC70843 | THRX-144644 |
THRX-144644 (THRX144644) is a potent, lung-selective ALK5 inhibitor with IC50 of 0.14 nM, inhibits p-SMAD3 in a BEAS2B cell line with IC50 of 23 nM;
THRX-144644 displays high selectivity in a broad secondary pharmacology panel with exception of e Lymphocyte CellSpecific Protein-Tyrosine Kinase (LCK, IC50=140 nM).
THRX-144644 demonstrated favorable TGFβ pathway pharmacodynamic inhibition in lung while minimizing key systemic toxicities.
More description
|
![]() |
DC70628 | MU1700 |
MU1700 is a potent, selective ALK1 (ACVRL1) and ALK2 (ACVR1) protein kinase inhibitor with IC50 of 13 and 6 nM, respectively.MU1700 inhibits only ALK1/2/6 and no additional off targets by kinome-wide screening against 369 protein kinases at 1 uM.MU1700 affects phosphorylation of SMAD1/5/8 that corresponds to BMP branch of signalling wchich is mediated also by ALK1/2 kinases.MU1700 is suitable chemical probe for in vivo disease models, and has remarkably high brain penetrance (mice, PO, 1 g/kg).
More description
|
![]() |
DC70582 | M4K2234 |
M4K2234 is a potent, selective ALK1 (ACVRL1) and ALK2 (ACVR1) protein kinase inhibitor with IC50 of 7 and 14 nM, respectively.M4K2234 inhibits only ALK1/2 and one additional off target (TNIK) by kinome-wide screening against 375 protein kinases at 1 uM.M4K2234 demonstrated in cell based target engagement assays with an IC50 of 83nM for ALK1 and 13 nM for ALK2.M4K2234 exhibits only very weak potency against ALK4/5.M4K2234 affects phosphorylation of SMAD1/5/8 that corresponds to BMP branch of signalling which is mediated, besides others, also by ALK1/2 kinases.M4K2234 has only a very weak effect on SMAD2/3 phosphorylation that corresponds to TGF beta branch of signalling which is mediated mostly via ALK4/5/7.
More description
|
![]() |
DC70182 | ALK2 R206H inhibitor 23 |
ALK2 R206H inhibitor 23 is a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2/ACVR1) with IC50 of 8 nM for mutant ALK2 R206H.ALK2 R206H inhibitor 23 displays >15-fold selectivity over ALK1/ALK3, and >100-fold over ALK5/ALK6.
More description
|
![]() |
DC49189 | Con B-1 |
ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells.
More description
|
![]() |
DC48380 | Iruplinalkib |
Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.
More description
|
![]() |
DC48379 | Zilurgisertib |
Zilurgisertib is a selective ALK 2 inhibitor for treating diseases such as cancer.
More description
|
![]() |
DC8138 | CEP-28122 Featured |
CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
More description
|
![]() |
DC8728 | CH5424802(Alectinib HCl) Featured |
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
More description
|
![]() |
DC8127 | KRCA-0008 Featured |
KRCA-0008 is a potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively).
More description
|
![]() |
DC8034 | LDN193189 free base Featured |
LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively.
More description
|
![]() |
DC47760 | ALK-IN-13 |
ALK-IN-13 is an ALK inhibitor, extracted from patent US20130225528A1, example 19.
More description
|
![]() |